Gulf Pharmaceutical Industries

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: AEG000201018
AED
1.23
-0.02 (-1.6%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Gulf Pharmaceutical Industries stock-summary
stock-summary
Gulf Pharmaceutical Industries
Pharmaceuticals & Biotechnology
Gulf Pharmaceutical Industries PSC (Julphar) is a United Arab Emirates-based public shareholding company engaged in manufacturing and selling of medicines, drugs and other types of pharmaceutical and medical compounds, in addition to cosmetic compounds. The Company maintains a range of product portfolio, which target major therapeutic segments, including endocrinology, anti-infective, cardiovascular and gastroenterology, over-the-counter, nephrology, dermatology, respiratory, metabolic and burn and wound management. The Company operates through a network of more than 10 manufacturing plants, and a logistics network. The Company has approximately 800 products in various dosage forms, and more in the pipeline. The Company’s subsidiaries include Mena Cool FZE, which is engaged in the transportation, and Julphar Pharmaceuticals PLC, which is engaged in Manufacturing of medicines, wrapping and packing materials.
Company Coordinates stock-summary
Company Details
Digdaga Airport Road, P.O.Box 997 RAS AL KHAIMAH CITY None : None
stock-summary
Tel: 971 7 2461461971 7 2045273
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summary Board of Directorsstock-summary
Management
Designation
Sheikh Faisal Al Qasimi
Independent Chairman of the Board
H.E. Hasan Al Zaabi
Independent Vice Chairman of the Board
Dr. Ali Al Zawawi
Member of the Board
Mr. Ahmad Al Hosni
Independent Member of the Board
Mr. Ahmed Al Naeem
Independent Member of the Board
Mr. Jamal Al Nuaimi
Independent Member of the Board
Mr. Abdullah Al Qasimi
Independent Member of the Board
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
348 Million
(Quarterly Results - Jun 2025)
Net Profit:
17 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

AED 1,409 Million (Micro Cap)

stock-summary
P/E

28.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.01

stock-summary
Return on Equity

5.76%

stock-summary
Price to Book

1.47